Ivabradine Chanelle Medical (Ivabradine Oxalate)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the natural pacemaker of the heart. Inhibiting this current reduces the spontaneous depolarisation rate of the node, leading to a slower heart rhythm while leaving contractile strength and blood pressure largely unchanged.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual’s clinical condition, heart‑rate targets, and tolerance. Healthcare professionals adjust the regimen according to approved labeling and patient response.

The safety of ivabradine in pregnancy and lactation has not been established. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also lower blood pressure, whereas ivabradine selectively inhibits the If current without affecting contractility or blood pressure. Ivabradine is often considered when patients cannot tolerate beta‑blockers or need additional rate reduction.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed until use.

Ivabradine Chanelle Medical is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed.

The most serious adverse events include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare cases of QT‑interval prolongation. Patients should be monitored for signs of excessively slow heart rate, palpitations, dizziness, or fainting, and seek medical attention promptly if these occur.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, acute myocardial infarction, uncontrolled hypotension, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.